{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dulai PS"],"funding":["NIDDK NIH HHS"],"pagination":["1288-1295"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9437635"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["117(8)"],"pubmed_abstract":["<h4>Introduction</h4>Limited guidance exists for the postdischarge care of patients with ulcerative colitis hospitalized for moderate-severe flares.<h4>Methods</h4>RAND methodology was used to establish appropriateness of inpatient and postdischarge steroid dosing, discharge criteria, follow-up, and postdischarge biologic or small molecule initiation. A literature review informed on the panel's voting, which occurred anonymously during 2 rounds before and after a moderated virtual session.<h4>Results</h4>Methylprednisolone 40-60 mg intravenous every 24 hours or hydrocortisone 100 mg intravenous 3 times daily is appropriate for inpatient management, with methylprednisolone 40 mg being appropriate if intolerant of higher doses. It is appropriate to discharge patients once rectal bleeding has"],"journal":["The American journal of gastroenterology"],"pubmed_title":["Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel."],"pmcid":["PMC9437635"],"funding_grant_id":["U34 DK126626"],"pubmed_authors":["Rai V","Tuskey A","Damas OM","Sofia MA","Hanauer SB","Sauk JS","Afzali A","Deepak P","Yarur AJ","Cross RK","Kochhar GS","Raffals LE","Levy AN","Dulai PS","Siegel CA","Hudesman D","Lukin D","Ananthakrishnan AN"],"additional_accession":[]},"is_claimable":false,"name":"Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel.","description":"<h4>Introduction</h4>Limited guidance exists for the postdischarge care of patients with ulcerative colitis hospitalized for moderate-severe flares.<h4>Methods</h4>RAND methodology was used to establish appropriateness of inpatient and postdischarge steroid dosing, discharge criteria, follow-up, and postdischarge biologic or small molecule initiation. A literature review informed on the panel's voting, which occurred anonymously during 2 rounds before and after a moderated virtual session.<h4>Results</h4>Methylprednisolone 40-60 mg intravenous every 24 hours or hydrocortisone 100 mg intravenous 3 times daily is appropriate for inpatient management, with methylprednisolone 40 mg being appropriate if intolerant of higher doses. It is appropriate to discharge patients once rectal bleeding has","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-04T20:07:15.616Z","creation":"2025-04-04T20:07:15.616Z"},"accession":"S-EPMC9437635","cross_references":{"pubmed":["35416799"],"doi":["10.14309/ajg.0000000000001775"]}}